ADIL NASDAQ
Adial Pharmaceuticals, Inc.
1W: +49.3%
1M: +26.4%
3M: -23.4%
YTD: -65.7%
1Y: +213.2%
3Y: -72.5%
5Y: -96.0%
$2.10
+0.04 (+1.94%)
Weekly Expected Move ±5.9%
$1
$1
$1
$1
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.0M
52W Range1.31-19
Volume1,770,322
Avg Volume119,963
Beta1.27
Dividend—
Analyst Ratings
Company Info
CEOCary John Claiborne
Employees5
SectorHealthcare
IndustryBiotechnology
IPO Date2018-07-27
Websiteadialpharma.com
1180 Seminole Trail
Charlottesville, VA 22901
US
Charlottesville, VA 22901
US
434 422 9800
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Latest News
12 Health Care Stocks Moving In Tuesday's Intraday Session
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Goodman Tony | A-Award | 26,510 | — | 2026-04-07 |
| Anderson J. Kermit | A-Award | 9,185 | $1.64 | 2026-04-07 |
| Schuyler Kevin | A-Award | 9,185 | — | 2026-04-07 |
| Shah Vinay | A-Award | 17,325 | — | 2026-04-07 |
| Gilliland Robertson | A-Award | 9,185 | — | 2026-04-07 |